Abstract
The development of the monoclonal antibodies daratumumab and elotuzumab has expanded treatment options for multiple myeloma and led to great improvement in patient outcomes. These agents have favorable safety profiles and synergize effectively with established agents used in the management of myeloma, namely immunomodulatory drugs and proteasome inhibitors. This article reviews the rationale for use of monoclonal antibodies in myeloma, current approved indications for daratumumab and elotuzumab, the manner in which these agents are used in the overall management of myeloma, and specific challenges associated with their use in the clinic. It also highlights other, emerging drug combinations that incorporate daratumumab or elotuzumab and profiles new therapeutic antibodies currently under development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 667-674 |
| Number of pages | 8 |
| Journal | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting |
| Issue number | 38 |
| DOIs | |
| State | Published - May 23 2018 |
| Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)